Kurt Hermann Bockhorst1, Robert Garcia2, Samson Kujit Gaddam2, Claudia S. Robertson2, Ponnada A. Narayana1
1DII, University of Texas, Houston, TX, United States; 2Neurosurgery, Baylor College of Medicine, Houston, TX, United States
mild traumatic brain injury (mTBI) affects millions of people each year. A treatment is unknown. He we present a potential therapeutic agent, eryrhropoietin, which has been shown to be beneficial in other brain injuries as TBI or global ischemia. We used MRI, especially DTI, to quantify the effects of erythropoietin on mTBI.